Repurposing: a golden opportunity for patient centric health investment in Europe

Widely researched and resourced during the early stages of the COVID-19 pandemic, repurposing has shown its worth in an emergency. Facilitating repurposing beyond the pandemic promises sustainable developments and patient centric health outcomes in a range of therapy areas, comments Medicines for Europe, the trade group that represents generic and biosimilars drugmakers in the region.

The upcoming European Union pharmaceutical legislation revision is the opportunity to recognize and support the concept of Value Added Medicines, including repurposed medicines and, in doing so, to recognize the potential for Europe.

To make medicine repurposing a success we need to employ all resources at hand to connect different actors. One such connection which can uniquely be addressed by the EU is to assist academia and non-commercial stakeholders in conducting research, as well as facilitating their partnering with the industry in making repurposed medicines available to patients.